[Stock Spotlight] Samick Pharm and Hyundai Pharm rise on US Veradermix hair-loss drug Phase 3 results
Predicted impact: Low
Stock move on a US peer's Phase 3 hair-loss result; not the company's own filing.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.